Pembrolizumab Plus Paclitaxel Extends Survival in Platinum-Resistant Ovarian Cancer
Phase 3 trial shows immunotherapy combination significantly improves progression-free and overall survival in recurrent ovarian cancer patients.
Summary
A large international phase 3 trial found that adding pembrolizumab (Keytruda) to weekly paclitaxel chemotherapy significantly extended both progression-free survival and overall survival in women with platinum-resistant recurrent ovarian cancer. The combination improved median overall survival from 14.0 to 17.7 months compared to paclitaxel alone. This represents an important advance for patients whose cancer has become resistant to platinum-based chemotherapy, offering a new treatment option that harnesses the immune system alongside traditional chemotherapy to fight cancer more effectively.
Detailed Summary
This landmark phase 3 trial addresses a critical unmet need in ovarian cancer treatment, where most patients eventually develop resistance to platinum-based chemotherapy and face limited treatment options with poor outcomes.
The ENGOT-ov65/KEYNOTE-B96 study enrolled 643 women across 187 centers in 25 countries who had platinum-resistant recurrent ovarian cancer and had received 1-2 prior treatments. Participants were randomly assigned to receive either pembrolizumab (an immune checkpoint inhibitor) plus weekly paclitaxel, or placebo plus paclitaxel. Bevacizumab could be added at physician discretion.
The results were compelling: pembrolizumab combination significantly improved progression-free survival (8.3 vs 6.4 months) and overall survival (17.7 vs 14.0 months). The benefits were consistent across different patient subgroups, including those with PD-L1 positive tumors who showed even greater improvements.
This represents a meaningful advance in ovarian cancer care, as platinum-resistant disease typically has a poor prognosis. The combination offers patients nearly 4 additional months of life on average, with some experiencing much longer benefits. The treatment was generally well-tolerated, though grade 3+ adverse events were more common with pembrolizumab (68% vs 55%).
These findings establish pembrolizumab plus paclitaxel as a new standard treatment option for platinum-resistant recurrent ovarian cancer, providing hope for patients facing this challenging diagnosis.
Key Findings
- Pembrolizumab plus paclitaxel extended overall survival by 3.7 months (17.7 vs 14.0 months)
- Progression-free survival improved by 1.9 months (8.3 vs 6.4 months)
- Benefits seen across patient subgroups, with greater effects in PD-L1 positive tumors
- Grade 3+ adverse events increased from 55% to 68% with pembrolizumab addition
- Treatment-related deaths occurred in 1% of pembrolizumab group vs 2% of control group
Methodology
Randomized, double-blind, placebo-controlled phase 3 trial conducted at 187 centers across 25 countries. Participants were stratified by planned bevacizumab use, geographic region, and PD-L1 expression levels.
Study Limitations
Summary based on abstract only. Safety profile shows increased toxicity with combination therapy. Long-term follow-up data and quality of life measures not available from abstract.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.